Profusa Signs Non-Binding Term Sheet to Acquire Commercial-Stage Diagnostics Firm, Reshuffles Management
PFSA is trading near its 52-week low of $1.6 (2.5% above the low) on light trading volume (0.1× avg).
Summary
Profusa announced a non-binding term sheet to acquire a commercial-stage diagnostics company, a potential pivot toward revenue-generating assets. The target's 2025 net revenues are estimated at approximately $111 million. Consideration includes common stock equal to 19.99% of Profusa's outstanding shares, with the remainder in non-voting convertible preferred stock. Profusa expects to close about $7 million in convertible note financing with a 12-month term, 9% OID, and 7% interest. Simultaneously, key management changes were announced: Jack Stover was appointed as Executive Chairman and CEO, and Ben Hwang transitioned into the role of President of Profusa. This follows a series of highly dilutive financing moves and a recent 1-for-25 reverse split to maintain Nasdaq listing. The acquisition, if completed, could provide a lifeline, but the non-binding nature keeps the impact uncertain. Watch for definitive agreement and financing terms.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The target's 2025 net revenues are estimated at approximately $111 million. Consideration includes common stock equal to 19.99% of Profusa's outstanding shares, with the remainder in non-voting convertible preferred stock. Profusa expects to close about $7 million in convertible note financing with a 12-month term, 9% OID, and 7% interest.
At the time of this announcement, PFSA was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $906.3K. The 52-week trading range was $1.60 to $4,162.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.